Arch Biopartners has initiated subject recruitment in its Phase II study aimed at assessing cilastatin’s efficacy in ...

CN (TSX: CNR) (NYSE: CNI) will issue its second-quarter 2025 financial and operating results after the market close.

You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply.

You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply.

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ('ZenaTech'), a business technology solution provider specializing in AI ...

Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the ...

Andrew Peller Limited (ADW.A / ADW.B) will issue its financial results for the three months ended June 30, 2025, after close of ...

TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private ...

Arch Biopartners, Inc. is a portfolio-based biotechnology company, which engages in the development of technologies that have the potential to make a significant medical or commercial impact. Its ...